Stroke Trial, Recruiting NCT06785740 Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT06785740
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 70 years of age or older at the time of their ischemic stroke or TIA (a "mini-stroke")
  • People who are enrolled within 6 weeks of being diagnosed with an ischemic stroke or TIA
  • People who were already taking a statin medication at the time of their stroke or TIA
  • People who are considered "frail" based on a specific scoring tool called the Clinical Frailty Scale — specifically, those with a pre-stroke score of 4–7 and/or a post-stroke score of 6–7 on that scale (confirm with trial site)

Who may not be able to join:

  • People who have previously had a serious reaction to statins, such as one that caused death, was life-threatening, required a hospital stay, caused lasting disability, or caused a birth defect — or people who have other medical reasons they cannot take statins
  • People who score 8 or higher on the Clinical Frailty Scale, meaning they are considered very severely frail or have a life expectancy of less than 6 months
  • People who are not able to communicate in Dutch
  • People who are unable to answer questions, even with the help of a trusted representative (such as a family member or carer)
  • People who are unwilling or unable to sign a written consent form, even with the help of a trusted representative

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Renske van den Berg-Vos, Prof. dr., Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Phone: 0031 20 566 9111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
1 September 2029

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Health-Related Quality of Life (HrQoL); Major Adverse Cardiovascular Events (MACE) free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov